Item |
Information |
Drug Groups
|
approved |
Description
|
An anthelmintic with schistosomicidal activity against Schistosoma mansoni, but not against other Schistosoma spp. Oxamniquine causes worms to shift from the mesenteric veins to the liver where the male worms are retained; the female worms return to the mesentery, but can no longer release eggs. (From Martidale, The Extra Pharmacopoeia, 31st ed, p121) |
Indication |
For treatment of Schistosomiasis caused by Schistosoma mansoni |
Pharmacology |
Oxamniquine is an anthelmintic with schistosomicidal activity against Schistosoma mansoni, but not against other Schistosoma spp. Oxamniquine causes worms to shift from the mesenteric veins to the liver where the male worms are retained; the female worms return to the mesentery, but can no longer release egg. |
Affected Organisms |
|
Biotransformation |
Probably hepatic |
Absorption |
Well absorbed orally |
Half Life |
1-2.5 hours |
References |
• |
Filho RP, de Souza Menezes CM, Pinto PL, Paula GA, Brandt CA, da Silveira MA: Design, synthesis, and in vivo evaluation of oxamniquine methacrylate and acrylamide prodrugs. Bioorg Med Chem. 2007 Feb 1;15(3):1229-36. Epub 2006 Nov 16.
[Pubmed]
|
• |
See General references, Filho et. al. for synthesis of oxamniquine methacylate. |
|
External Links |
|
|